Anavex Appoints Contract Research Organizations to Initiate Phase I/IIa Clinical Programs, Regulatory Strategies in Alzheimer’s Disease

Califon, NJ/Basel, Switzerland/Dresden, Germany – August 10, 2010 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced that it has signed a definitive master services agreement with Genesis BioPharma Group (“Genesis”) and ABX-CRO Advanced Pharmaceutical Services (“ABX-CRO”) to begin clinical studies and regulatory filings  for ANAVEX 2-73, its lead compound for the treatment of…